Skip to content
Evigrade
CriticalProkinetic, 5-HT4 serotonin receptor agonist (withdrawn EU/US)×Prokinetic, peripheral dopamine D2 receptor antagonist

Updated · Methodology

Mechanism

The Spanish domperidone summary of product characteristics (SmPC) contraindicates domperidone with drugs that prolong the QT interval and carry a risk of torsade de pointes, and attributes the contraindication to a higher risk of QT prolongation from pharmacodynamic or pharmacokinetic interactions. It names cisapride among these drugs (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Domperidone itself is associated with QT prolongation. Epidemiological studies also link it to a higher risk of serious ventricular arrhythmias and sudden cardiac death, especially in people over 60, at doses above 30 mg a day, and with QT-prolonging drugs (AEMPS). According to the erythromycin SmPC, high blood levels of cisapride can prolong the QT interval and cause arrhythmias, including ventricular tachycardia, ventricular fibrillation and torsade de pointes (erythromycin SmPC, AEMPS). The documents do not say whether domperidone and cisapride change each other's levels.

Symptoms

QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. With domperidone, QT prolongation and torsade de pointes have been reported very rarely, and these reports included people with other risk factors, electrolyte disturbances or concomitant medicines (domperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The risk of arrhythmia is higher with low or high potassium, low magnesium or a slow heart rate (domperidone SmPC, AEMPS).

Management

The combination is contraindicated. The Spanish domperidone summary of product characteristics (SmPC) contraindicates domperidone with QT-prolonging drugs and names cisapride among gastrointestinal medicines (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Cisapride is not in the Spanish medicines register CIMA and has no current US prescribing information, so the level of risk comes from the domperidone SmPC. If a person takes cisapride obtained in another country, do not prescribe domperidone (AEMPS). Domperidone is also contraindicated in known QT prolongation, significant electrolyte disturbances, bradycardia and heart disease such as congestive heart failure (AEMPS). If domperidone and cisapride have nevertheless been taken together and signs of arrhythmia appear, stop domperidone (AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Cisapride

Other interactions with Domperidone